Skip to main content
. 2023 Sep 11;55(4):229–236. doi: 10.4103/ijp.ijp_762_20

Table 2.

Demographic and clinical characteristics of patients receiving colistin and polymyxin B

Parametersa CMS (n=108) PMB (n=54) P
Age (years) 56.57±16.20 58.09±15.83 0.572
Gender, male 74 (68.5) 42 (77.8) 0.218
Weight (kg) 68.79±9.33 67.74±10.59 0.522
Baseline creatinine clearance (mL/min) 117.15±88.25 89.79±107.31 0.086
CCI score 4.28±2.00 3.81±2.14 0.178
ICU admission 60 (55.6) 40 (74.1) 0.022
APACHE-II score 20.87±1.72 18.75±3.89 0.002
Causative MDR bacteria
Klebsiella pneumoniae 55 (50.9) 32 (59.3) 0.316
Pseudomonas aeruginosa 30 (27.8) 13 (24.1) 0.615
Acinetobacter baumannii 18 (16.7) 8 (14.8) 0.762
Escherichia coli 10 (9.3) 1 (1.9) 0.077
 Other Gram-negative bacteria 18 (16.7) 6 (11.1) 0.348
Type of infection
 Pneumonia 8 (7.4) 4 (7.4) 1.000
 Bloodstream infection 66 (61.1) 35 (64.8) 0.774
 UTI 27 (25) 6 (11.1) 0.039
 Skin and soft-tissue infection 8 (7.4) 6 (11.1) 0.429
 Other internal infections 13 (12) 3 (5.6) 0.192
Concomitant nephrotoxic agents 11 (10.2) 11 (20.4) 0.074
 Vancomycin 9 (8.3) 10 (18.5) 0.058
 Aminoglycosides 1 (0.9) 1 (1.8) 0.605
 Furosemide IV 4 (3.7) 2 (3.7) 1.000
Comorbidities* 80 (74.1) 38 (70.4) 0.617
 DM 44 (40.7) 13 (24.1) 0.036
 Hypertension 58 (53.7) 25 (46.3) 0.505
 CAD 20 (18.5) 12 (22.2) 0.595
 Malignancy 22 (20.4) 9 (16.7) 0.646
 Dyslipidemia 20 (18.5) 5 (9.3) 0.124
 AKI 13 (12) 3 (5.6) 0.306
 CKD 4 (3.7) 6 (11.1) 0.133
 Others 27 (25) 14 (25.9) 0.898

*Cumulative percentage of comorbidities exceeds 100%, since a patient can have >1 comorbid condition, aData are presented as mean±SD or n (%). CMS=Colistimethate sodium, PMB=Polymyxin B, CCI=Charlson comorbidity index, APACHE-II=Acute Physiology and Chronic Health Evaluation II, ICU=Intensive care unit, CAD=Coronary artery disease, AKI=Acute kidney injury, CKD=Chronic kidney disease, MDR=Multidrug-resistant, UTI=Urinary tract infection, DM=Diabetes mellitus, SD=Standard deviation